Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups. The benefits of bevacizumab (Avastin) for the ...

A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for approximately 2 years after initial administration, aligning with outcomes in ...

Objective To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...